Moderate

Mixed connective tissue disease (MCTD; Sharp syndrome)

Mixed connective tissue disease · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Overlap connective tissue disease defined by high-titre anti-U1-RNP antibody plus features of SLE, systemic sclerosis and polymyositis occurring together or sequentially. Classic triad/clues: Raynaud phenomenon, swollen ('puffy') hands/sausage digits, and anti-U1-RNP positivity, with arthritis, myositis, oesophageal dysmotility and sclerodactyly. Course variable; pulmonary arterial hypertension is the leading cause of death. May evolve into a dominant single CTD (often SSc or SLE) over time. Treatment follows the dominant organ involvement.

Red flags

  • Exertional breathlessness/syncope/right heart strain — pulmonary arterial hypertension (leading cause of death)
  • Progressive proximal weakness + raised CK — significant myositis
  • Dysphagia/aspiration — oesophageal dysmotility
  • New hypertension + AKI — scleroderma-overlap renal crisis (ACE inhibitor)
  • High anti-RNP with evolving diffuse skin — transformation to systemic sclerosis

Assessment

Differential diagnosis

  • SLE (anti-dsDNA/Sm, nephritis more prominent, low complement)
  • Systemic sclerosis (anticentromere/Scl-70, more fibrosis)
  • Polymyositis/dermatomyositis (myositis-specific antibodies)
  • Undifferentiated connective tissue disease (features insufficient for a defined CTD)
  • Rheumatoid arthritis overlap (anti-CCP positive, erosive)

Investigations

  • ANA (high-titre speckled) + anti-U1-RNP (hallmark; required for diagnosis)
  • Anti-dsDNA/anti-Sm (usually negative — their presence suggests SLE instead)
  • CK, LDH, aldolase (myositis); EMG/MRI/muscle biopsy if weakness
  • FBC, U&E, urinalysis (cytopenias, renal involvement less common than SLE)
  • Echocardiography + NT-proBNP annually (pulmonary hypertension screen) + PFTs/HRCT for ILD
  • Nailfold capillaroscopy (SSc pattern); oesophageal studies if dysphagia

Management

  • Confirm anti-U1-RNP positivity with compatible clinical overlap features; exclude a dominant single CTD
  • Treat by dominant manifestation — there is no MCTD-specific regimen
  • Arthralgia/arthritis + fatigue: hydroxychloroquine +/- NSAIDs; methotrexate for persistent arthritis
  • Raynaud: cold avoidance + calcium-channel blocker (see Raynaud entry); vasodilators for digital ulcers
  • Myositis: glucocorticoids + steroid-sparing agent (methotrexate/azathioprine); IVIG if severe
  • Serositis/moderate systemic flare: glucocorticoids + immunosuppressant (azathioprine/mycophenolate)
  • Screen and aggressively manage pulmonary arterial hypertension and ILD (refer PH/respiratory centre)
  • Long-term monitoring for evolution into SSc/SLE and for PAH — leading cause of mortality

Drugs & doses

Hydroxychloroquine 200-400 mg ORALLY daily (max 5 mg/kg/day) for arthritis/skin/fatigue
NSAID e.g. naproxen 500 mg ORALLY twice daily with PPI for arthralgia/serositis
Nifedipine MR 10-20 mg ORALLY twice daily (or amlodipine) for Raynaud [verify local dose]
Prednisolone 0.5-1 mg/kg/day ORALLY for myositis/serositis/significant flare, then taper [verify local dose]
Methotrexate 15-25 mg weekly + folic acid, or azathioprine 1-2.5 mg/kg/day, or mycophenolate mofetil — steroid-sparing [verify local]
IVIG 2 g/kg over 2-5 days for refractory myositis [verify local]
PAH therapy (PDE5 inhibitor + endothelin receptor antagonist) via specialist PH centre [verify local]
PPI e.g. omeprazole 20-40 mg daily for oesophageal reflux/dysmotility

Disposition

Outpatient rheumatology with PH/respiratory surveillance. Admit for PAH decompensation, severe myositis, aspiration or renal crisis.

Complications & pitfalls

  • Pulmonary arterial hypertension (major mortality driver)
  • Interstitial lung disease
  • Inflammatory myopathy, oesophageal dysmotility/aspiration
  • Evolution to a dominant CTD (SSc or SLE)
  • Digital ischaemia from Raynaud

Exam pearls

  • Anti-U1-RNP is the defining antibody; absence of anti-dsDNA/Sm helps separate MCTD from SLE.
  • Pulmonary arterial hypertension — not renal disease — is the leading cause of death; screen with annual echo + NT-proBNP.
  • MCTD tends to be more steroid-responsive than pure SSc, but watch for renal-crisis risk if sclerodermatous.
  • 'Puffy hands' + Raynaud + high-titre speckled ANA should prompt anti-RNP testing.
  • Treat the dominant organ phenotype — there is no single MCTD protocol.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.